Titan’s stock dropped by 2.4% as the company reported a slight dip in Q3 net profit, despite a 25% YoY increase in total income. The reduction in customs duty on gold impacted profitability. Analysts are optimistic, with Macquarie and Goldman Sachs maintaining their positive ratings on Titan.
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.